Blindness: Clinical Trials

10 trials for Blindness, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed. 10 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 310Completed 10
Phase 21Completed 1

Follow Blindness: new trials by email Literature Review of Blindness trials Research Report on Blindness

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of the Benefit of Early Treatment With an Endothelin Inhibitor (Bosentan) in Patients With Sudden Blindness Due to Giant Cell Arteritis: CECIBO
treatment - Arteritis, Giant Cell, Blindness and Low Vision
Phase 3CompletedCentre Hospitalier Universitaire de Nice82020-02-042026-06-18
Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration
Aflibercept - Macular Degeneration, Wet Macular Degeneration
Phase 3CompletedCentre Hospitalier Intercommunal Creteil842013-12-012026-10-27
Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception
tasimelteon - Non-24-Hour Sleep-Wake Disorder
Phase 3CompletedVanda Pharmaceuticals2002011-10-012015-04-21
Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder
tasimelteon, Placebo - Non-24-Hour Sleep-Wake Disorder
Phase 3CompletedVanda Pharmaceuticals202011-09-012014-10-10
Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder
tasimelteon, Placebo - Non-24-Hour Sleep-Wake Disorder
Phase 3CompletedVanda Pharmaceuticals1362010-08-012014-10-16
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)
Ranibizumab, Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) - Macular Degeneration
Phase 3CompletedBayer12402008-04-012014-12-12
Preventing Depression in Patients With Macular Degeneration
Problem Solving Treatment, Control - Depression, Macular Degeneration
Phase 3CompletedThomas Jefferson University2062001-02-012014-01-08
Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity
Supplemental Oxygen Management, Conventional Oxygen Management - Infant, Newborn, Infant, Low Birth Weight
Phase 2 / Phase 3CompletedNICHD Neonatal Research Network6491994-02-012015-06-08
Early Treatment Diabetic Retinopathy Study (ETDRS)
Aspirin, Argon Laser Photocoagulation - Blindness, Diabetic Retinopathy
Phase 3CompletedNational Eye Institute (NEI)1979-12-012006-09-04
Diabetic Retinopathy Study (DRS)
Xenon Photocoagulation, Argon Photocoagulation, Photocoagulation - Diabetic Retinopathy, Blindness
Phase 3CompletedNational Eye Institute (NEI)1972-01-012006-06-02

Narrower conditions

Eye Diseases (5)  ·  Chronobiology Disorders (3)  ·  Dyssomnias (3)  ·  Macular Degeneration (3)  ·  Nervous System Diseases (3)  ·  Sleep Disorders, Circadian Rhythm (3)  ·  Sleep Wake Disorders (3)  ·  Vision Disorders (3)  ·  Diabetic Retinopathy (2)  ·  Retinal Diseases (2)  ·  Depression (1)  ·  Depressive Disorder (1)  ·  Giant Cell Arteritis (1)  ·  Premature Birth (1)

Broader conditions

Neurologic Manifestations (10)  ·  Pathological Conditions, Signs and Symptoms (10)  ·  Sensation Disorders (10)  ·  Signs and Symptoms (10)  ·  Nervous System Diseases (7)  ·  Vision Disorders (7)  ·  Eye Diseases (5)  ·  Mental Disorders (4)  ·  Retinal Diseases (4)  ·  Cardiovascular Diseases (3)  ·  Occupational Diseases (3)  ·  Vascular Diseases (3)  ·  Diabetes Complications (2)  ·  Diabetes Mellitus (2)  ·  Diabetic Angiopathies (2)

Interventions

tasimelteon (3)  ·  aflibercept (2)  ·  Aspirin (1)  ·  Light Coagulation (1)  ·  Ranibizumab (1)  ·  Therapeutics (1)

Sponsors

Vanda Pharmaceuticals (3)  ·  National Eye Institute (NEI) (2)  ·  Bayer (1)  ·  Centre Hospitalier Intercommunal Creteil (1)  ·  Centre Hospitalier Universitaire de Nice (1)  ·  NICHD Neonatal Research Network (1)  ·  Thomas Jefferson University (1)

Countries

United States (5)  ·  France (3)  ·  Germany (2)  ·  Argentina (1)  ·  Australia (1)  ·  Austria (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Colombia (1)  ·  Czechia (1)  ·  Hungary (1)  ·  India (1)  ·  Israel (1)  ·  Italy (1)  ·  Japan (1)

Top investigators

Alan R. Spitzer, MD (1)  ·  Barbara J. Stoll, MD (1)  ·  Beverly S. Brozanski, MD (1)  ·  Charles C. Barr, MD (1)  ·  Cynthia Cole, MD (1)  ·  Dale L. Phelps, MD (1)  ·  David Easa, MD (1)  ·  David K. Stevenson, MD (1)  ·  Edward F. Donovan, MD (1)  ·  Eric Souied, MD (1)  ·  Frank W. Kokomoor, MD (1)  ·  J. David Bradford, MD (1)  ·  James A. Lemons, MD (1)

Results publications

PMID 26466871, PMID 10654946, PMID 17679633, PMID 23084240, PMID 23528439, PMID 24084500, PMID 25107900, PMID 25439429, PMID 30681643, PMID 31826853, PMID 36932356

NIH funding

M01RR000054 (1), M01RR000070 (1), R01MH061331 (1), U10HD021385 (1), U10HD021415 (1), U10HD027851 (1), U10HD027853 (1), U10HD027856 (1), U10HD027871 (1), U10HD027880 (1), U10HD027904 (1), U10HD040689 (1)